Results 101 to 110 of about 2,758 (199)

Ravulizumab and Efgartigimod in Myasthenia Gravis

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +4 more sources

mRNA-1273/ravulizumab [PDF]

Reactions Weekly, 2021
openaire   +1 more source

Translating biomarker insights into practice: a path forward in TA-TMA management

Frontiers in Medicine
Recent advances in the management of transplant-associated thrombotic microangiopathy (TA-TMA) include the harmonization of diagnostic criteria and the identification of high-risk disease features.
Sonata Jodele, Eleni Gavriilaki
doaj   +1 more source

Refocusing generalized myasthenia gravis : Patient burden, disease profiles, and the role of evolving therapy [PDF]

Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy.
Cortés-Vicente, Elena, Jacob, Saiju, Saccà, F., Salort-Campana, E., Schneider-Gold, C., Universitat Autònoma de Barcelona   +5 more
core   +1 more source

[Horizon Scanning Of Therapeutic Alternatives For Generalized Myasthenia Gravis And Five-Year Healthcare Expenditure Forecast Model] [PDF]

OBJECTIVE: The objective of the analysis was to assess and quantify the economic impact of generalized Myasthenia Gravis (gMG) in Italy over the next five years (2025—2029) using Horizon Scanning and expenditure forecasting methodologies.METHODS: The ...
Adami, Silvia, Alboni, Paolo Emilio, Bitonti, Rossella, Colalillo, Emanuele, Cristinziano, Adriano, La Seta, Concetta, Marinozzi, Andrea   +6 more
core   +2 more sources

Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long‐term aplastic anemia treatment

Clinical Case Reports
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors ...
Kazuki Sakurai, Kei Saito, Shunsuke Hatta, Yuna Katsuoka, Kuniaki Meguro, Hisayuki Yokoyama, Toru Izumi   +6 more
doaj   +1 more source

Treating myasthenia gravis beyond the eye clinic [PDF]

Myasthenia gravis (MG) is one of the most well characterised autoimmune disorders affecting the neuromuscular junction with autoantibodies targeting the acetylcholine receptor (AChR) complex.
Jacob, Saiju
core   +1 more source

Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

Health and Quality of Life Outcomes
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder. Symptoms such as fatigue can have a substantial impact on patients’ physical activity levels, sleep, quality of life, and work productivity. Ravulizumab treatment can
Elizabeth A. Griffiths, Jae S. Min, Wei-Nchih Lee, Jeffrey C. Yu, Yogesh Patel, Karl-Johan Myren, David Dingli   +6 more
doaj   +1 more source

Neuromyelitis Optica Spectrum Disorders – from pathophysiology to treatment [PDF]

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune diseases characterized by severe, inflammatory attacks predominantly affecting the optic nerves and spinal cord and central nervous system.
Bochenek, Oliwia, Kałuża, Jessica Adriana, Konaszczuk, Adrian, Koper, Mateusz, Kozyra, Oliwia, Nowak, Aleksandra, Paluch, Katarzyna, Ratyna, Klaudia, Skarbek, Małgorzata, Szypuła, Zofia   +9 more
core   +1 more source

Two‐decade battle with myasthenia gravis: A breakthrough case report on the long‐term success with eculizumab and ravulizumab treatment

Clinical Case Reports
Key Clinical Message This unique case of generalized myasthenia gravis shows sustained stability of a patient's condition for 3 years with eculizumab/ravulizumab treatment following 16 years of refractory disease.
Stefan Quasthoff
doaj   +1 more source